Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer

Molecular Imaging

Volumn 7, Issue 1, 2008, Pages 12-20

  Kwee, Sandi A ^a   Thibault, Gregory P ^b   Stack, Richard S ^b   Coel, Marc N ^b   Furusato, Bungo ^b   Sesterhenn, Isabell A ^b  

^a Hamamatsu/Queen's PET Imaging Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; POSITRON EMISSION TOMOGRAPHY (PET); PROSTATE TUMORS; RADICAL PROSTATECTOMY (RP); REGION -OF-INTEREST (ROI); TUMOR VOLUMES;

CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROCHOLINE;

AGED; ARTICLE; EVALUATION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; PROSTATECTOMY; ROC CURVE;

AGED; CHOLINE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROC CURVE;

EID: 44949142966     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2008.00002     Document Type: Article

References (27)

1. Basillote JB, Armenakas NA, Hochberg DA, Fracchia JA. Influence of prostate volume in the detection of prostate cancer. Urology 2003;61:167-71.
2. Naughton CK, Miller DC, Mager DE, et al. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 2000;164:388-92.
3. Rabbani F, Stroumbakis N, Kava BR, et al. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998; 159:1247-50.
4. Djavan B, Mazal P, Zlotta A, et al. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study. Prostate 2001;47:111-7.
5. Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000;163:1144-8; discussion 1148-9.
6. el-Gabry EA, Halpern EJ, Strup SE, Gomella LG. Imaging prostate cancer: current and future applications. Oncology (Huntingt) 2001;15:325-36; discussion 339-42.
7. Graser A, Heuck A, Sommer B, et al. Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology. AJR Am J Roentgenol 2007;188:84-90.
8. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234:804-14.
9. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805-14.
10. Kurhanewicz J, Vigneron DB, Hricak H, et al Three-dimensional H-1MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology l996;l98:795-805.
11. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296:580-3.
12. Epstein JI, Lecksell K, Carter HB. Prostate cancer sampled on sextant needle biopsy: significance of cancer on multiple cores from different areas of the prostate. Urology 1999;54:291-4.
13. Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with l8 fluorine fluorocholine positron emission tomography. J Urol 2005;173:252-5.
14. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000;164:400-4.
15. Lim J, Dorman E, Cabral C. Automated production of [18F]FECh and [18F]FCH: preparation and use of [18F]fluoroalkane sulfonates and fluoroalkylation agents. J Label Compd Radiopharm 2003;46 Suppl l:S46.
16. Muzic RF Jr, Chen CH, Nelson AD. A method to correct for scatter, spillover, and partial volume effects in region of interest analysis in PET. IEEE Trans Med Imaging 1998;17:202-13.
17. Chen CH, Muzic RF Jr, Nelson AD, Adler LP. Simultaneous recovery of size and radioactivity concentration of small spheroids with PET data. J Nucl Med l999;40:118-30.
18. Mullerad M, Hricak H, Kuroiwa K, et al. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 2005;174:2158-63.
19. Farsad M, Schiavina R, Castellucci P, et al. Detection and localization of prostate cancer: correlation of (11 )C-choline PET/ CT with histopathologic step-section analysis. J Nucl Med 2005;46: 1642-9.
20. Costouros NG, Coakley FV, Westphalen AC, et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2007;188:812-6.
21. Starney TA, Freiha FS, McNeal JE, et al. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(3 Suppl):933-8.
22. Crawford ED, Hirano D, Werahera PN, et al. Computer modeling of prostate biopsy: tumor size and location - not clinical significance - determine cancer detection. J Urol 1998;159:1260-4.
23. Choi YK, Johnson WO, Thurmond MC. Diagnosis using predictive probabilities without cut-offs. Stat Med 2006;25:699-717.
24. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235:623-8.
25. DeGrado TR, Reiman RE, Price DT, et al. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 2002;43:92-6.
26. Kwee SA, Wei H, Sesterhenn 1, et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006;47:262-9.
27. Surti S, Karp JS, Popescu LM, et al. Investigation of time-of-flight benefit for fully 3-D PET. IEEE Trans Med Imaging 2006;25:529-38.